Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
TV

NASDAQ · TVGN

Tevogen Bio Holdings Inc.

Healthcare · Biotechnology

$5.90

Down-$0.15 (-2.48%)

Updated Nov 2, 2026, 5:44 AM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
85.1M
P/E ratio
-2.7
Dividend yield
0.00%
52-week range
$3.64 – $32.50
Volume
2.99K
Avg. volume
795.94K

Price performance · TVGN

TVGN price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

TVGN closed at $5.90 after 20 trading sessions, down 10.61% for the selected period.

Last close
$5.90
Period change
-10.61%
Period low
$5.90
Period high
$7.11
Daily close
View OHLC price history
TVGN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$5.95$6.32$5.80$5.902.99K
Oct 29, 2026$6.08$6.40$5.87$6.0519.03K
Oct 28, 2026$6.11$7.00$6.00$6.2421.47K
Oct 27, 2026$6.12$6.70$6.12$6.285.14K
Oct 26, 2026$6.52$6.70$6.19$6.259.43K
Oct 23, 2026$6.81$6.81$6.35$6.5339.41K
Oct 22, 2026$6.58$7.15$6.58$6.8135.95K
Oct 21, 2026$6.4401$6.4401$6.4401$6.4401737
Oct 20, 2026$6.70$6.85$6.70$6.821.7K
Oct 19, 2026$6.855$7.10$6.77$6.771.91K
Oct 16, 2026$6.899$7.07$6.75$7.072.3K
Oct 15, 2026$6.38$7.09$6.38$7.081.51K
Oct 14, 2026$6.77$7.10$6.4047$6.50562.5K
Oct 13, 2026$6.57$7.11$6.50$7.114.33K
Oct 12, 2026$6.9917$6.9917$6.4231$6.67853.35K
Oct 9, 2026$7.15$7.15$6.78$6.782.75K
Oct 8, 2026$6.68$7.435$5.87$7.0630.17K
Oct 7, 2026$7.10$7.10$6.49$6.491.76K
Oct 6, 2026$6.56$6.56$6.4606$6.492.84K
Oct 5, 2026$6.898$6.97$6.57$6.603.48K

Latest TVGN news

The latest Smart Investors Daily articles mentioning TVGN.

Stock researchCompany · Overview

TVGN research

Overview

Company profile and research snapshot.

Company profile

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
TVGN recent ratings
DateFirmRatingTarget
Mar 4, 2026D. Boral CapitalHold—
Mar 3, 2026D. Boral CapitalBuy—
Nov 20, 2025D. Boral CapitalBuy—
Sep 4, 2025D. Boral CapitalBuy—
Aug 18, 2025D. Boral CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 8, 2026

UPDATE – Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC

WARREN, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), an integrated healthcare enterprise combining biopharma, artificial intelligence, and healthcare services to improve the affordability and accessibility of life-saving medicines, today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with HRK Healthcare LLC (“HRK”). If consummated, the proposed transaction co

Yahoo · Oct 8, 2026

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC

WARREN, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), an integrated healthcare enterprise combining biopharma, artificial intelligence, and healthcare services to improve the affordability and accessibility of life-saving medicines, today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with HRK Healthcare LLC (“HRK”). If consummated, the proposed transaction co

Yahoo · Sep 30, 2026

Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements

Both previously disclosed Nasdaq compliance matters are now closedWARREN, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), an integrated healthcare enterprise combining biotechnology, artificial intelligence, and healthcare services to improve the affordability and accessibility of life-saving medicines, today announced that it received written notice from The Nasdaq Stock Market LLC (“Nasdaq”)on September 29, 2026, confirming that the Company ha

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By